Best Life Sciences Companies in Leiden, Netherlands
The 68 best Life Sciences companies in Leiden, Netherlands in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Crucell.
Our analysis of 576 Life Sciences companies
$91.7b in tracked funding; 70% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Leiden
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Crucell Crucell researches and develops products and markets vaccines, proteins and antibodies for the treatment of… | $443M | 125 mo ago | 1,300 | — | Acquired | — | — |
| 2 | Pharvaris Orally deliverable bradykinin B2 antagonists for hereditary angioedema | $164M | 67 mo ago | 66 | Berndt Modig Co-founder & CEO | Public | 4 patents Novel small‑molecule bradykinin B2 receptor antagonists for therapeutic use | 2 job openings |
| 3 | Vico Developer of RNA modulating therapies for genetic neurological diseases | $103M | 24 mo ago | 38 | Judith Van Deutekom Scientific Co-Founder and Advisor | Series B | — | — |
| 4 | Varmx Therapeutic proteins to restore blood clotting in bleeding patients | $77M | 37 mo ago | 10 | Pieter Reitsma Founder | Series B | — | — |
| 5 | proqr therapeutics ProQR Therapeutics is a biotech company focused on developments of drugs to treat genetic disorders. | $58M | 71 mo ago | 148 | — | Public | 362 patents Antisense oligonucleotide therapeutics enabling RNA editing for metabolic, liver, cardiovascular, and neurological diseases. | 1 launch |
| 6 | ISA Pharmaceuticals Developer of therapeutic vaccines for cancer and infectious diseases | $41M | 59 mo ago | 44 | — | Series B | 90 patents Peptide-based cancer vaccines and immunogenic formulations combined with PD‑1 inhibition | — |
| 7 | Anavo Therapeutics Developer of drugs for cancer treatment | $33M | 37 mo ago | 10 | Birgit Zech CEO | Seed | 3 patents Small-molecule WIP1 phosphatase inhibitors for cancer therapy | 1 job opening |
| 8 | ProFibrix Powdered fibrin sealant for surgical bleeding | $33M | 178 mo ago | 25 | — | Acquired | 112 patents Recombinant fibrinogen production and dry‑powder hemostatic delivery device technologies. | — |
| 9 | Mimetas Develops microfluidics-based organ-on-a-chip tissue models | $29M | 45 mo ago | 108 | Paul Vulto Co-Founder & Co-CEO | Series B | 86 patents Microfluidic organ-on-a-chip platforms for 3D tissue and vascular modeling | 1 launch |
| 10 | Azafaros Developer of small molecule based therapeutics for the treatment of rare metabolic disorders | $28M | 13 mo ago | 17 | Stefano Portolano CEO | Series B | 50 patents Small-molecule drugs targeting lysosomal storage disorders, especially gangliosidosis therapies. | 1 award |
| 11 | Artica Therapeutics Developer of small molecule therapeutics for immunological disorders | $13M | 31 mo ago | — | Arwin Ridder Co-Founder | Seed | — | — |
| 12 | Amarna Therapeutics Developer of immune-modulating gene therapies for rare and prevalent autoimmune diseases and genetic diseases | $11M | 80 mo ago | 30 | Marjanne Messie CFO | Series A | 5 patents Patents concentrated in chemistry & materials | — |
| 13 | ProteoNic Provider of products and services for improving recombinant protein production levels | $8M | 176 mo ago | 20 | Frank Pieper CEO | Series A | — | — |
| 14 | DCprime Developer of immunotherapeutic solutions for treating cancer | $7M | 124 mo ago | 25 | — | Acquired | 50 patents Novel dendritic cell-based cancer vaccines and tumor‑independent antigen immunotherapies | — |
| 15 | MyLife Technologies Developer of a nanotech-based drug delivery system | $4M | 55 mo ago | 12 | — | Series A | — | — |
| 16 | Facio Therapies Provider of small molecule therapeutics for Facioscapulohumeral Dystrophy | $3M | 128 mo ago | 7 | David Dasberg CEO | Series A | — | — |
| 17 | Genewity Biotech company focused on commercializing potentially groundbreaking therapies in the field of cell and gene… | $3M | 39 mo ago | — | Arno Bisschop Co-Founder & CEO | Funding Raised | 2 patents Artificial thymus creation for immune cell therapy and regenerative immunology | — |
| 18 | Toxys Developer of In vitro genotoxicity testing services | $2M | 75 mo ago | 23 | — | Public | 3 patents In vitro embryonic development assays for toxicology and drug safety evaluation. | 2 launchs |
| 19 | DNage Develops therapies for ageing diseases caused by DNA damage | $2M | 254 mo ago | — | Jan Hoeijmakers Co-Founder | Acquired | — | — |
| 20 | IPD Provider of treatment for prosthetic joint & metal implant infections | $2M | 60 mo ago | 2 | Richard Wateringen CEO | Seed | — | — |
| 21 | GenomeScan Provider of next-generation genome sequencing and testing | $1M | 43 mo ago | 38 | Peter Belt CEO | Funding Raised | — | — |
| 22 | BaseClear Contract service laboratory with a focus on DNA technology, genomics and synthetic biology. | $1M | 82 mo ago | 96 | — | Funding Raised | — | 1 job opening · 1 internship |
| 23 | XS Innovations Developer of medical device for chronic kidney disease treatments | $1M | 21 mo ago | — | Joris Rotmans Co-Founder | Seed | 50 patents Patents concentrated in health & consumer products | — |
| 24 | Aeon Astron Biotech company focusing on development and marketing of biomaterials and regenerative medical technology for… | $937K | 125 mo ago | 44 | Michael Lai CEO & Chairman | Deadpooled | — | — |
| 25 | VitroScan Provider of a diagnostic platform for precision treatments for cancer patients | $901K | 18 mo ago | 6 | Willemijn Vader Managing Director | Seed | 10 patents Tumor organoid immune-response measurement platforms for personalized immunotherapy | 1 partnership |
| 26 | ZF-Screens Platform for high-throughput screening of pharmaceutical drug candidates against diseases. | $632K | 134 mo ago | — | Ron Dirks CEO | Deadpooled | 3 patents In vivo high-throughput screening platforms for biological assay automation | — |
| 27 | Levels Developer of diagnostic tools for the treatment of infectious diseases | $417K | 30 mo ago | — | Blandine Tallec Co-Founder | Seed | — | — |
| 28 | Amylon Developer of RNA therapeutics for rare beta-amyloid related diseases | $348K | 103 mo ago | 2 | Daniel de Boer Co-Founder | Seed | — | — |
| 29 | Imuno Therapeutics Developer of drug discovery and precision therapy platform for oncology | $340K | 55 mo ago | 5 | Jan Verhoef Founder | Seed | — | — |
| 30 | Fibriant Develops variants of fibrinogen protein for therapeuticapplication | $316K | 50 mo ago | 9 | Jaap Koopman CEO | Seed | 17 patents Fibrinogen-based adjuvant formulations enhancing antimicrobial and therapeutic peptide efficacy | — |
| 31 | ZoBio Provider of fragment-based drug discovery services | $278K | 123 mo ago | 43 | — | Acquired | — | 1 launch |
| 32 | BIMINI Biotech Developer of therapeutics for the treatment of cancer | $238K | 17 mo ago | 4 | Ger Strous Co-Founder | Seed | — | 1 expansion |
| 33 | SysBioSim System biology service provider | $123K | 101 mo ago | — | Basak Tektemur Altay Founder & CEO | Funding Raised | — | — |
| 34 | NightWatch Provider of wearable device for epilepsy seizure detection during sleep | $110K | 74 mo ago | 3 | Mark Bloemendaal Co-Founder | Series A | — | — |
Top 12 Life Sciences companies in Leiden
#1
Series B · Leiden, South Holland · founded 2018 · 17 employees$27.5Mraised▾
Developer of small molecule based therapeutics for the treatment of rare metabolic disorders. It has developed products for patients suffering from lysosomal storage disorders (LSDs) and LSD-related diseases. The compounds interfere with the metabolism of glycolipids that is disturbed in these patients.
- May 2025Series B$146M
- Feb 2020Series A$27.5M
- Jul 2018Seed—
#2
Series B · Leiden, South Holland · founded 2019 · 38 employees$103.3Mraised▾
Developer of RNA modulating therapies for genetic neurological diseases. The company uses VICOMER antisense oligonucleotide platform to design RNA modulating therapeutics to address specific genetic defects such as Rett syndrome, Alzheimer’s disease, Huntington disease, and more. The company's lead candidate is VO659 for multiple polyglutamine disorders, spinocerebellar ataxia type 3 and type 1 and Huntington’s disease.
- Jun 2024Series B$12.3M
- Jan 2024Series B$60M
- Jul 2020Series A$31M
#3
Series B · Leiden, South Holland · founded 2015 · 10 employees$77.2Mraised▾
VarmX, a spin-out company from the Leiden University Medical Center, is focussed on development and manufacturing of therapeutic proteins to restore blood clotting in bleeding patients. Its lead product PseudoXa is a modified recombinant human coagulation factor X and is being developed to restore blood clotting in the presence of direct factor Xa anticoagulants (DOACS) such as rivaroxaban, apixaban, and edoxaban. DOACS are taken by patients for the prevention and treatment of thrombosis and stroke, but as a side effect severe bleeding often occurs.
- May 2023Series B$32.3M
- Sep 2022Grant (prize money)$2.5M
- Oct 2021Grant (prize money)—
- 2021Grant (prize money)$56.5K
#4
Seed · Leiden, South Holland · founded 2016 · 6 employees$901.3Kraised▾
Provider of a diagnostic platform for precision treatments for cancer patients. The company offers a 3D drug response platform that helps in predicting the drug reactions on the tumor cultures for drug optimization solutions. The platform gives insights by a systematic approach for measuring drug activity via advanced imaging technology and drug response analysis for better clinical outcomes.
- Dec 2024Grant (prize money)$2M
- Apr 2019Seed$901.3K
#5
Seed · Leiden, South Holland · founded 2013$1.2Mraised▾
Developer of medical device for chronic kidney disease treatments. It offers Dynamic AVF that opens the arteriovenous fistula to establish high blood flow for hemodialysis and closes the fistula to restore to normal blood circulation between sessions
- Sep 2024Seed$1.2M
#6
Seed · Leiden, South Holland · founded 2019 · 4 employees$238.1Kraised▾
Developer of therapeutics for the treatment of cancer. The company's drug candidates include BM001, BM002, and BM003 which render the growth hormone receptor dysfunctional making the cells less sensitive to growth hormone.
- Jan 2025Seed$3.1M
- Nov 2020Seed$238.1K
#7
Seed · Leiden, South Holland · founded 2020 · 10 employees$33.3Mraised▾
Developer of drugs for cancer treatment. The company is developing small molecule modulators of phosphatase and kinase activity that will help in cancer treatment.
- May 2023Seed$9.3M
- Apr 2021Seed$24M
#8
Seed · Leiden, South Holland · founded 2020$12.7Mraised▾
Developer of small molecule therapeutics for immunological disorders. It offers covalent drugs based on covalent binding technology as well as in label-free cellular-based screening approaches for the treatment of inflammatory and autoimmune indications.
- Nov 2023Seed$12.7M
#9
Public · Leiden, South Holland · founded 2015 · 66 employees$164.2Mraised▾
Pharvaris is a preclinical stage company developing orally deliverable drugs for hereditary angioedema (HAE). The lead candidate, PHA121 is a bradykinin B2 receptor competitive antagonist & demonstrated activity in bradykinin-mediated disease models. The company is advancing this molecule into IND-enabling studies.
- Nov 2020Series C$80M
- Sep 2019Series B$66M
- 2015Series A$18.2M
#10
Acquired · Leiden, South Holland · founded 1993 · 1300 employees$443Mraised▾
Crucell focused on research development, production and marketing of vaccines, proteins and antibodies that prevent and/or treat infectious diseases. Crucell’s core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and aluminum-free hepatitis A vaccine.
- Jan 2016Grant (prize money)$92.1K
- Sep 2009PE$443M
#11
Series B · Leiden, South Holland · founded 2013 · 108 employees$28.9Mraised▾
Mimetas develops organ-on-a-chip tissue models for evaluating drugs, chemicals, and food components. The products OrganoPlates, OrganoReady, OrganoTEER, and OrganoFlow are microfluidics-based culture plates for in-vitro tissue culture. It enables culturing and screening of 3D organ and tissue models, predicting toxic side effects, drug efficacy, and validates customized disease, toxicology, and transport models.
- Sep 2022Grant (prize money)$272.8K
- Aug 2021Grant (prize money)$59K
- Sep 2020Grant (prize money)$2.2M
- Jun 2020Grant (prize money)$66.9K
#12
Series B · Leiden, South Holland · founded 2004 · 44 employees$40.5Mraised▾
Developer of therapeutic vaccines for cancer and infectious diseases. The drug pipeline includes ISA101 which consists of13 synthetic long peptides derived from the E6 and E7 oncogenic proteins of the HPV 16 virus for the treatment of human papillomavirus type 16 induced diseases, including cervical cancer, most anogenital premalignant and malignant lesions, and head and neck cancer, and others.
- Jul 2021Series B$30M
- Oct 2019Conventional Debt$22.1M
- Dec 2017Grant (prize money)$2M
- Jan 2013Series A$10.6M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology in Leiden is moving
A read on the academic research around Biotechnology in Leiden — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 62 papers.
- Leiden University Medical Center43
- Leiden University23
- University of Applied Sciences Leiden2
- Messenger RNA3
- Antibody3
- Gene3
- Induced pluripotent stem cell3
- Ribonucleoprotein2
- Immune system3
- Epitope2
- Peptide2
- Biological pest control2
- Receptor2
- Proteome1
- Apoptosis1
- In vivo1
- Cell culture1
- Signal transduction1
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.